Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Deals

Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization

Fineline Cube Feb 27, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...

Company Drug

Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review

Fineline Cube Feb 27, 2023

China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Jacobio Pharma Partners with WestChina-Frontier for Preclinical Safety Studies

Fineline Cube Feb 27, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a partnership agreement with compatriot firm WestChina-Frontier PharmaTech,...

Company Drug

Mabwell’s IL-11 Monoclonal Antibody 9MW3811 Approved for Australian Clinical Trial

Fineline Cube Feb 27, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving clinical trial approval from...

Company Drug

AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval

Fineline Cube Feb 27, 2023

UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at...

Company Deals

CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research

Fineline Cube Feb 27, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Deals

Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center

Fineline Cube Feb 27, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai...

Company Deals Digital

Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services

Fineline Cube Feb 24, 2023

Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed...

Company Drug

CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA

Fineline Cube Feb 24, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...

Company Deals

Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development

Fineline Cube Feb 24, 2023

Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...

Company Drug

CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs

Fineline Cube Feb 24, 2023

The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...

Company Drug

InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study

Fineline Cube Feb 24, 2023

China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...

Company Drug

Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials

Fineline Cube Feb 24, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...

Company Deals

Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration

Fineline Cube Feb 24, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China...

Company Medical Device

NMPA Approves STmed’s ECMO Product for Market

Fineline Cube Feb 24, 2023

The National Medical Products Administration (NMPA) has approved STmed Technology’s extracorporeal cardiopulmonary support auxiliary equipment...

Company Medical Device

Johnson & Johnson MedTech’s QDOT Catheter Approved in China for Atrial Fibrillation

Fineline Cube Feb 24, 2023

Johnson & Johnson MedTech’s next-generation QDOT micro diagnostic/ablation deflectable tip catheter, a disposable pressure monitoring...

Company Deals

Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto

Fineline Cube Feb 24, 2023

US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...

Company Deals

ConjuStar Peptide-Drug Conjugate Angel Financing

Fineline Cube Feb 24, 2023

Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...

Policy / Regulatory

Guangdong Adds Hospitals to GBA Drug and Device Green Channel

Fineline Cube Feb 23, 2023

The Health Commission of Guangdong Province (GDHC) has released a second list of designated medical...

Company Drug

Zai Lab to Present Zejula OS Study Results at ESMO Congress

Fineline Cube Feb 23, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...

Posts pagination

1 … 505 506 507 … 612

Recent updates

  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
  • AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
  • HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod
  • Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.